about
HIV-1 diversity, transmission dynamics and primary drug resistance in AngolaHighly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic.Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in AngolaOn the contribution of Angola to the initial spread of HIV-1.Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.Origin and epidemiological history of HIV-1 CRF14_BG.Predictors of attrition and immunological failure in HIV-1 patients on highly active antiretroviral therapy from different healthcare settings in Mozambique.Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.Baseline susceptibility of primary HIV-2 to entry inhibitors.Donor-Recipient Identification in Para- and Poly-phyletic Trees Under Alternative HIV-1 Transmission Hypotheses Using Approximate Bayesian Computation.High genetic diversity of human immunodeficiency virus type 1 in Angola.Genetic diversity and drug resistance profiles in HIV type 1- and HIV type 2-infected patients from Cape Verde Islands.Evaluation of the diagnostic performance of the rapid test VIKIA HIV1/2 in a highly complex HIV-1 epidemic.HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique.Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women.Rapid clinical progression to AIDS and death in a persistently seronegative HIV-1 infected heterosexual young manSeronegative infection and AIDS caused by an A2 subsubtype HIV-1In vitro evaluation of novel reverse transcriptase inhibitors TAF and OBP-601 against multi-drug resistant primary isolates of HIV-2Accidental Father-to-Son HIV-1 Transmission During the Seroconversion PeriodCorrection to "Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides"Spiro-Lactams as Novel Antimicrobial AgentsA Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing AntibodiesMetagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillanceAuthor Correction: Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance
P50
Q28542528-852A000D-8070-4D78-9B6D-4DF3260C6AB6Q30370063-2E8437B5-B7ED-4355-AE90-60CF1A3311EFQ30387160-D2810D94-8E60-4D8C-8EB9-785D9CD9FFB8Q30391799-7A868F28-DF53-4977-9DFD-5E5B2293E64DQ33591409-882999D9-9CFE-4287-9F8A-524C9EFFC856Q33809419-E377ED06-F672-4816-99D2-4127A87EF6CFQ34039423-7F6C92A2-012C-4F5B-9991-FD46C9F47FF9Q35077691-71AA7B33-74DE-418A-9301-65EC5FB7CD09Q35156353-169D409D-B220-49E1-B348-106986DBE2CAQ37247746-50FEE1D8-2CCA-4051-BC94-100E4CE55CA5Q38915512-114E2F96-E036-448F-854A-D0B064DF6623Q40040133-7E93E44D-4F2E-4D61-A39B-77C8F72A0D69Q43425262-A642863A-A499-42A1-9D36-99579D955599Q46638450-3EC52609-1FF7-4F88-847C-025BDAE712BAQ46700373-DB11A399-4486-47AE-B91D-8626D31A8026Q46986567-8AE6EC19-FAF8-4EDD-A0CC-AA28CBA9C7A4Q52580522-A6E71019-8782-42BF-91D9-D39C7A6C8C6CQ56971842-4983DDF8-59BA-4AAE-A7B5-A536EE194AA3Q56971870-4660F61C-659A-4DC4-B9CC-79D30F0BD6DBQ58542679-FD35C9E6-8A57-4872-B968-7AFD255CA411Q58870939-3DC2B43D-C9D2-4C5D-96C8-9A0FA79E1DF4Q91152098-A399B0F7-511F-4272-B97F-820C7719CE07Q91186253-C4275953-BA3C-4848-BEBF-D43C9EA2B1BAQ91779794-4A83BFC0-F0A6-489E-90B4-AD0CC6405A6AQ92610614-2EE5E137-5F14-4E84-A854-D6C5EC629706Q92825630-A0814EDA-604E-4A79-8ED1-A2D6C8494651
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Inês Bártolo
@ast
Inês Bártolo
@en
Inês Bártolo
@es
Inês Bártolo
@nl
type
label
Inês Bártolo
@ast
Inês Bártolo
@en
Inês Bártolo
@es
Inês Bártolo
@nl
prefLabel
Inês Bártolo
@ast
Inês Bártolo
@en
Inês Bártolo
@es
Inês Bártolo
@nl
P106
P1153
8418824400
P21
P31
P496
0000-0002-2022-8921